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Abstract 
Purpose: To evaluate the antitumor activity of gemcitabine (GEM), incorporated in microemulsions with 
varying surfactant-to-oil (S/O) ratio, against MCF-7 breast cancer cells and HCT 116 colon cancer cells.  
Methods: The microemulsion formulations consisted of Tween 80, Span 20, isopropyl myristate (IPM) 
and aqueous ethanol (40 %). Anticancer assessment involved determination of hemolysis activity, 
screening for cytotoxicity using sulphorhodamine B assay and determination of the mechanism of cell 
death using light microscope and ApopNexin FITC apoptosis detection kit. 
Results: Hemolysis activity of all the microemulsion formulations, either blank or drug-loaded, was 
significantly less than that of GEM solution.  On average, MCF-7 cell viability significantly (p < 0.05) 
decreased from 38.53 ± 6.04 to 30.1 ± 4.66 % when the administered microemulsion concentration in 
modified eagle medium (MEM),  increased from 0.03 to 0.3 % v/v but significantly (p < 0.05) increased 
by 1.4-fold when exposed to GEM solution at equivalent concentrations. In contrast, the cytotoxicity of 
the microemulsion formulation against HCT116 cells was similar to that of 0.03 % v/v GEM solution but 
greater than that of GEM solution by 1.5-fold when their concentration in MEM increased to 0.3 %v/v. 
Microscopic studies show that the microemulsions stimulated apoptosis in MCF-7 and HCT116 cell 
within 48 h and at low concentration (0.03 %v/v). 
Conclusion: Microemulsion formulations improved the efficacy of GEM and induced apoptosis in MCF-
7 and HCT116 cells.  
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Chemotherapy involves the use of low molecular 
weight drugs to selectively destroy tumor cells or 
at least limit their proliferation.  Antitumor drugs 
can be classified according to their mode of 
action, such as DNA-interactive agents, 
antimetabolites, antitubulin agents, molecular 
targeting agents and other biological agents [1].  
In spite of the advancement in the 
pharmaceutical industries of producing 
chemotherapeutic agents, cancer treatment is 
still challenging. In fact, the chemotherapeutic 
agents have several delivery issues including 
poor selectivity for target tissues, severe side 
effects in healthy tissues, rapid clearance, and 
susceptibility to induce drug resistance [2]. 
Gemcitabine (GEM), dFdC 2′, 2′-difluoro-2′-
deoxycytidine, is a low molecular weight, 
deoxycytidine analogue, inhibitor of cellular DNA 
synthesis [3] and is effective against many solid 
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tumors [4]. However, it has a very short half-life 
of 8 min elimination because it gets degraded by 
the plasma deaminases.  Therefore, it is used in 
high doses and hence, cause severe side effects 
[5]. Many research studies have recently 
proposed delivery systems for GEM that would 
improve its efficiency and reduce its side effects 
[2, 6-10]. One of these delivery systems was 
microemulsion [11].  
Microemulsion, a single optically isotropic and 
thermodynamically stable liquid solution, is a 
colloidal system that consists of water, oil and 
amphiphile. There are three types of 
microemulsions which are most likely to be 
formed depending on the compositions: oil-in-
water (o/w), water-in-oil (w/oil) and bicontinuous 
microemulsions. Microemulsions have recently 
played a great role in cancer therapy, either by 
delivering anticancer agents or by producing the 
nanoparticulate of the chemotherapeutic agents 
[12]. The objective of this study was to evaluate 
the microemulsion system, proposed by Tsai et 
al [11] for delivering GEM to bladder cancer, for 
GEM activity against MCF-7 breast and HCT116 
colon cancer cells.  
EXPERIMENTAL 
MATERIALS AND CELL LINES  
Polyoxyethylene sorbitan monooleate (tween 80) 
was purchased from El-Nasr Pharmaceutical 
Chemicals Co (Egypt). Isopropyl Myristate (IPM) 
was obtained from Jamjoom Pharma (Jeddah, 
KSA) while ethanol was purchased from Fisher 
Chemical (UK).  Sorbitan monolaurate (Span 20), 
modified eagle medium (MEM), vitamins solution, 
fetal calf serum (FCS),  non-essential amino 
acid, penicillin streptomycin, phenol red, 
phosphate buffered saline, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid buffer solution 
(HEPES), trypsin, sulforhodamine B (SRB), 
trichloroacetic acid (TCA)  and pure gemcitabine 
were purchased from Sigma-Aldrich Chemical 
Co.  (MO, USA). The distilled water was purified 
using a water purification system from Bibby 
sterilin ltd, (UK). ApopNexin Annexin V FITC 
Apoptosis Kit (Lot no. 2053919) was purchased 
from Millipore (MA, USA).  All other reagents 
were of analytical grade. MCF-7 and HCT-116 
cell lines were generously donated by Tissue 
Culture Bank of King Fahd Medical Research 
Center, Jeddah, Saudi Arabia.  
Formation of the microemulsion  
 
Three microemulsion systems were produced by 
mixing Tween 80, Span 20, IPM and distilled 
water containing 40 % ethanol, as described by 
Tsai et al [11].  The surfactant-to-oil (S/O) ratio of 
the three microemulsions, M1, M2 and M3, were 
4:1, 0.8:1 and 3:1 respectively. GEM was 
incorporated in the microemulsions by directly 
adding 1 mg/ml of GEM to the microemulsion, 
and labeled as M1-D, M2-D and M3-D.   
 
Hemolysis assay of microemulsion formu-
lations 
 
Hemolytic assay was carried out using the 
method of Bulmus et al [13]. Freshly collected 
human red blood cells (5 ml) were washed three 
times with 150 mM NaCl and centrifuged at 2500 
rpm for 10 min. The serum was removed and the 
cells were suspended in 100 mM sodium 
phosphate buffer (pH 7.4). An appropriate 
amount of the test samples, i.e., 10 µl of 
microemulsion (M1, M2 and M3), 10 µl of 1 
mg/ml of GEM-loaded microemulsion (M1-D, M2-
D and M3-D) and 10 µl of 1 mg/ml of GEM 
dissolved in water, were mixed with 200 µl of red 
blood cells solution and the final reaction mixture 
volume made up to 1 ml by adding sodium 
phosphate buffer (pH 7.4). The reaction mixture 
was placed in a water bath at 37 °C for 1 h. After 
the incubation period, the reaction mixture was 
centrifuged again at 2500 rpm for 15 min. The 
supernatant was collected and its optical density 
was measured at 541 nm, using sodium 
phosphate buffer (pH 7.4) as blank. Deionized 
water was used as a positive control. The 
experiment was performed in triplicate and the 
hemolytic activity (%) was calculated as in Eq 1. 
 
Hemolytic activity (%) = {(As – Ab)/Ac}100 ……… (1) 
 
where As, Ab and Ac are the absorbance of 
sample, blank and positive control, respectively. 
 
Cell culture  
The human cell lines, MCF-7 breast cancer and 
HCT-116 colon cancer, were cultivated, as 
described by Alkhatib and Albishi [14], in a cell 
culture flask (25 cm2) containing 10 ml of MEM 
media supplemented with vitamins solution, non-
essential amino acid, penicillin streptomycin, 
phenol red, HEPES and 10 %v/v heat inactivated 
fetal calf serum (FCS) at 37 °C in a 95 % air and 
5 % humidified CO2 incubator. Medium was 
changed every 48 h intervals until confluence. 
Then, confluent cells were obtained by 
trypsinization, washed and passaged every 3 
days. The experimental cells were incubated in 
10 % of MEM culture medium for 24 h in a 95 % 
air and 5 % humidified CO2 incubator at 37 °C. 
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Scanning of cell toxicity using SRB assay 
 
The assay was performed according to the 
method of Skehan et al [15]. Cells were 
cultivated at a density of 1 x104 cells in flat-
bottomed tissue culture plates containing 0.1 ml 
of growth medium. A 200 μl of 0.03 and 0.3 %v/v 
of the test samples, diluted in MEM culture 
medium, microemulsions (M1, M2 and M3), 1 
mg/ml of GEM loaded in microemulsion (M1-D, 
M2-D and M3-D) and 1 mg/ml of GEM dissolved 
in water were added to the cells. Experiments for 
each test sample were implemented in triplicate. 
Untreated cells were used as control. The cell 
toxicity of the tested sample against the MCF-7 
and HCT-116 cells was assessed by measuring 
the ratio of dead cells to vital cells as in Eq 2.  
 
Cell viability (%) = (As/Ac)100 ………….……….. (2) 
 
where As is the absorbance of the cells treated 
with the test sample and Ac is the absorbance of 
the untreated cells. Both preparations were 
measured at 490 nm using MR 7000 ELISA 
reader (Dynatech Laboratories Inc., Chantilly, 
Va.) 
 
Evaluation of mechanism of cell death 
 
Amounts (each of 1 x105) of MCF-7 and HCT-
116 cells were seeded into flat-bottomed tissue 
culture plates containing 0.1 ml of growth 
medium. Quantities (200 μl each) of 0.03 and 0.3 
%v/v of microemulsion (M1, M2 and M3), 1mg/ml 
of GEM-loaded microemulsion (M1-D, M2-D and 
M3-D) and 1 mg/ml of aqueous GEM solution 
were administered to the cells and left for 48 h. 
The treated cells were washed twice with 
phosphate buffer (pH 7.2) for 5 min and fixed by 
the addition of 4 % formaldehyde. The fixation 
solution was discarded and the cells stained with 
10 % coomassie blue dye for 10 min. Finally, the 
stain was washed with tap water twice, and left to 
dry overnight at 25 oC. Morphological changes 
were observed by phase-contrast inverted 
microscope (model 1X17, Olympus, Japan).  
 
Detection of early signs of apoptosis  
 
ApopNexin FITC assay was used to detect early 
signs of apoptosis by staining the cells with a 
green fluorescent system obtained from the 
binding between Annexin V and 
phosphatidylserine translocate from the inner 
membrane of the cell to the cell surface during 
apoptosis. The experiments were performed as 
mentioned in the protocol of ApopNexin FITC kit 
(Lot no. 2053919). An aliquot (200 μl) of 0.3 %v/v 
of microemulsion (M1), 1 mg/ml of GEM-loaded 
in microemulsion (M1-D) and 1 mg/ml of 
aqueous GEM were introduced into the cells. 
Untreated cells were used as control. 
Statistical analysis 
 
All values were expressed as mean ± standard 
deviation, each experiment being performed in 
triplicate. Statistical analyses were performed 
with one-way analysis of variance (ANOVA) test, 
two-way ANOVA test and independent sample t-
test using MegaStat. Differences were 




HEMOLYTIC EFFECT OF MICROEMUL-
SION FORMULATIONS 
 
As illustrated in Figure 1, the highest hemolysis 
(36.77 ± 4.20 %) was recorded when aqueous 
GEM solution was introduced, indicating that it 
has the largest effect on red blood cells. The 
microemulsions, M1 and M2, have hemolytic 
activity of 9.72 ± 2.47 and 7.18 ± 1.93 %, 
respectively, which are significantly less than the 
hemolytic effect of M1-D and M2-D with values of 
17.27 ± 0.14 and 21.37 ± 3.70 %, respectively. 
On the other hand, M3 and M3-D showed similar 
hemolytic activities of 21.38 ± 3.49 and 21.53 ± 
3.41 %, respectively. It is worth noting that 
among the GEM-loaded-microemulsions, M1-D 
with the least S/O ratio had the least effect on the 
red blood cells hemolysis activity of 17.27 ± 0.14 
%. 
 
Figure 1: The percentages of hemolysis activity of 10 
µl of microemulsion solutions (M1, M2, M3), 10 µl of 
1mg/ml of GEM loaded in microemulsions (M1-D, M2-
D and M3-D) and 10 µl of 1mg/ml of GEM dissolved in 
water. All of the experiments were performed in 
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Table 1:  Cytotoxic activity of 0.03 and 0.3% v/v of microemulsions (M1, M2 and M3), GEM-loaded-
microemulsions (M1-D, M2-D and M3-D), and aqueous GEM solution against MCF-7 and HCT-116 using SRB 
assay (mean ± SD, n = 3) 
 
Microemulsion MCF-7 HCT-116 
0.03% 0.3% 0.03% 0.3% 
M1 35.84±4.68 26.18±1.76 53.35±2.66 31.29±7.80 
M1-D 30.27±7.41 26.08±3.59 62.93±5.95 32.85±5.89 
M2 46.45±10.39 29.22±1.19 63.00±7.55 36.93±4.74 
M2-D 37.80±4.79 34.71±7.71 57.33±6.92 37.12±3.37 
M3 45.95±4.51 31.29±7.80 54.76±2.15 32.17±11.81 
M3-D 34.92±4.46 32.85±5.89 65.64±7.52 37.03±3.64 
GEM 54.28±3.17 42.3±5.70 51.22±2.89 50.84±1.31 
 
Cell toxicity of microemulsions  
 
As demonstrated in Table 1, the viability of MCF-
7 and HCT-116 cells varied treatment with 0.03 
%v/v  and 0.3 %v/v of the tested microemulsion 
samples. The anti-proliferative effect of all of the 
microemulsion formulations against MCF-7, 
either drug-free or drug-loaded, were significantly 
(P < 0.05) more than the GEM solution. 
Changing the concentration in MEM from 0.03 to 
0.3 %v/v did not improve the cytotoxic effect of 
all of the GEM loaded-microemulsions (M1-D, 
M2-D and M3-D) and GEM solution against 
MCF-7 cells. In contrast, increasing the 
concentration in MEM of all the microemulsion 
formulations (M1/M1-D, M2/M2-D and M3/M3-D) 
10-fold significantly (P < 0.05) improved their 
cytotoxicity effect against HCT116 cells while 
varying the concentration of GEM solution did not 
change its cytotoxicity. In fact, the cytotoxic effect 
of 0.03 % aqueous GEM solution against 
HCT116 was similar to that of the microemulsion 
formulations (M1/M1-D, M2/M2-D and M3/M3-D) 
but significantly (P < 0.05) less than when 
applied at a concentration of 0.3 %. It is worth 
noting that there were no significant differences  
(P ≥ 0.05) in cytotoxicity against both MCF-7 and 
HCT116 for M1/M1-D, M2/M2-D and M3/M3-D 
when applied at the same concentration. 
 
Mechanism of cell death  
 
Morphology is an important indicator of the status 
of cells. In order to understand the mechanism of 
cell death of the drug-free and drug-loaded 
microemulsion formulations at a concentration of 
0.03 and 0.3%v/v when administered into MCF-7 
and HCT-116 cells, the cells morphologies were 
visualized using light microscope. In general, 
slight changes in cells shape, decreased total 
number of cells and increased intracellular space 
of the cells treated with 0.03% (v/v) of drug-free 
and drug loaded-microemulsion formulations 
were observed compared with the untreated cells 
whereas cells treated with 0.3 %v/v of the tested 
microemulsion formulas have shown dramatic 
changes in shape, extremely increased 
intracellular space and clearance of cells 
(Figures 2 and 3). On the other hand, there was 
no noticeable difference between the cells 
treated with either 0.03 or 0.3 %v/v of GEM 
solution except little changes in the morphology 
of the cells.  
 
MCF-7 cells were not obviously affected by all of 
the microemulsion formulations at 0.03 %v/v as 
shown in Figure 2A. They only displayed earlier 
stages of apoptosis as more intracellular spaces 
were observed without noticeable changes in the 
shape of the cells. In contrast, they were more 
affected by the entire formulations at 0.3 %v/v. 
As shown in Figure 2B, they exhibited late stages 
of apoptosis through the complete formation of 
fragmented apoptotic bodies resulted from the 
enormous killed cells.  
 
On the other hand, HCT-116 cells treated with 
the drug-free and drug-loaded microemulsion 
formulations showed varying levels of cell death 
as shown in Figure 3. The cells treated with 0.03 
%v/v of each of the microemulsion formulations 
showed earlier stages of apoptosis as they 
shrunk and their chromatin became more 
condensed. On the other hand, 0.3 %v/v 
microemulsions clearly killed most of the cells, 
suggesting that the cells had undergone late 
stages of apoptosis.  On the other hand, 
aqueous GEM solution did not display signs of 
apoptosis as clearly as the microemulsions.   
 
Effect of GEM-loaded microemulsions on 
apoptosis induction of cancer cells  
 
As shown in Figure 4, the untreated cells did not 
stain positively which indicates the viability of 
cells, while MCF-7 and HCT116 cells treated with 
0.3 % of M1, M1-D and GEM solution were 
stained positively with green fluorescent which 
implies signs of apoptosis due to the 
externalization of phosphatidylserine caused by 
the cell surface outbreak.   
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Figure 2: Light microscopic images showing morphological changes in MCF-7 cells treated with (A) 0.03 %v/v 




Figure 3: Light microscopy images showing morphological changes in HCT116 cells treated with (A) 0.03 %v/v 
and (B) 0.3 %v/v of microemulsion formulas and aqueous GEM solution. Images were magnified at x 200. 
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Figure 4: Fluorescent microscopic images of (A) MCF-7 cells and (B) HCT116 cells labeled with Annexin V. All 




GEM is a chemotherapeutic agent that is used to 
treat various types of carcinomas, such as breast 
cancer, ovarian cancer, non-small cell lung 
cancer, head and neck cancers, pancreatic 
cancer and colon cancer [3]. The synergistic 
mechanism of action of GEM is based on 
destroying cancer cells undergoing DNA 
synthesis which result in apoptosis induction. 
Therefore, it has several side effects [8] and has 
to be used in high concentrations and in 
combination with other agents [9,10]. Many 
studies have suggested delivery systems that 
would improve the efficiency of GEM against 
various cancers and reduce its side effects [2, 6-
8]. 
 
In this study, it has been found that the 
hemolysis activities of all of the microemulsion 
formulations, either drug-free or loaded with 
drug, were significantly less than GEM solution. 
Therefore, incorporation of GEM in micro-
emulsion reduced its cytotoxicity against 
erythrocytes, thus minimizing what is considered 
one of the major drawbacks of this drug [16]. Our 
findings were in agreement with those of Singh et 
al [17] who reported that GEM-loaded folic acid 
conjugated multi-walled carbon nanotubes have 
significantly less hemolytic toxicity. In fact, Wilk 
et al [18] found out that surfactant structure and 
the critical micelle concentration play a critical 
role in damaging the red blood cells.  
 
The cytotoxicity of the drug-free microemulsions 
was similar to the drug-loaded microemulsions 
which indicate that the components of the 
microemulsion are interfering with the 
biochemical assay results. Li et al [19] have 
demonstrated that Tween 80 affected the results 
of MTT assay, which is similar to SRB assay, 
when screening for the cytotoxicity of drugs by 
detecting biochemical changes on the cell 
membrane. When Tsai et al [11] administered 
the drug-free microemulsions into the rats, they 
found out that the microemulsions caused 
inflammation according to their histological 
evaluation of rat bladder tissues. They also have 
showed that GEM release from the 
microemulsion formulations is within 8h, which 
indicates the complete release of the drug from 
the microemulsion formulations into the cells 
within 48 h incubation, the time used in our 
study.  
 
Moreover, the cytotoxicity of the microemulsion 
formulations and GEM solution against MCF-7, 
determined by SRB assay, were not sensitive to 
concentration variations. There was a significant 
change in the morphologies of the cells when the 
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concentration of the microemulsion formulations 
increased from 0.03 to 0.3 %v/v, while the for 
GEM solution matched with what was visualized 
under light microscope. In other words, 
increasing the concentration of GEM solution did 
not enhance its efficiency as much as was the 
case with GEM-loaded-microemulsion. On the 
other hand, the cytotoxicity of the microemulsion 
formulations against HCT116 cells were very 
sensitive to concentration variation, and this was 
confirmed by the results of light microscopy and 
the ApopNexin assay. Similarly, the cytotoxicity 
of aqueous GEM solution against HCT 116 was 
not sensitive to concentration change even when 
concentration increased 10-fold. 
 
A previous study showed that encapsulating 
GEM in liposomes improved its antitumor effect 
by 4.6- and 7.9-fold within 72 h when its 
concentration increased from 1 to 100 μM, 
respectively [6]. Another study found that 
chitosan nanoparticle of GEM demonstrated 
improved antiproliferative effect over free GEM 
when it was administered to mice-bearing L1210 
wt subcutaneous tumor [2]. The nanoparticle 
formulation enhanced the permeability of GEM 
into the tumor which resulted in a superior tumor 
regression.  Furthermore, Yang et al [20] have 
delivered GEM in multiwalled carbon nanotubes 
with magnetic properties which would selectively 




Incorporation of GEM in microemulsions 
decreases cytotoxicity against erythrocytes. 
microemulsion improves the efficiency of GEM 
and induces apoptosis in cancer cells. 
Consequently, recommended to establish in vivo 
studies are recommended to determine if a 
similar finding can be replicated in the body 
tissues. Further studies are also required to 
elucidate the mechanisms responsible for the 





The authors wish to express sincere appreciation 
to King Abdulaziz City for Science and 
Technology for its financial support for the 
research project (no. P-S-612-11), King 
Abdulaziz University Hospital for providing cell 
cultures and King Fahd Medical Research 




1. Thurston, DE. Chemistry and Pharmacology of 
Anticancer Drugs, CRC Press, Taylor and Francis 
Group, LLC; Boca Raton, FL; 2007; p 312.  
2. Arias JL, Reddy H, Couvreur P. Superior preclinical 
efficacy of gemcitabine developed as chitosan 
nanoparticulate system, Biomacromolecules 2011; 
12: 97–104. 
3. Vandana M, Sahoo, SK.  Long circulation and cytotoxicity 
of PEGylated gemcitabine and its potential for the 
treatment of pancreatic cancer, Biomaterials 2010; 
31(35): 9340-9356. 
4. Hodge LS, Taub ME, Tracy TS.  Effect of its deaminated 
metabolite, 2′, m2′-difluorodeoxyuridine, on the 
transport and toxicity of gemcitabine in HeLa cells, 
Biochem Pharmacol 2011; 81(7): 950-956. 
5. Reddy LH,  Couvreur P. Novel approaches to deliver 
gemcitabine to cancers, Curr Pharm 2008; 14: 1124–
1137. 
6. Celano M, Calvagno MG, Bulotta S,  Paolino D,  Arturi F,  
Rotiroti  D,  Filetti S,  Fresta M,  Russo D. Cytotoxic 
effects of Gemcitabine-loaded liposomes in human 
anaplastic thyroid carcinoma cells, BMC Cancer 
2004; 4: 63-67. 
7. Patra CR,   Bhattacharya R, Wang E, Katarya A, Lau JS, 
Dutta S, Muders M, Wang S, Buhrow SA, Safgren 
SL, et al. Targeted Delivery of Gemcitabine to 
Pancreatic Adenocarcinoma Using Cetuximab as a 
Targeting Agent, Cancer Res 2008; 68(6): 1970-
1978.  
8. Arsawang U, Saengsawang O, Rungrotmongkol T, 
Sornmee P, Wittayanarakul K, Remsungnen T, 
Hannongbua S. How do carbon nanotubes serve as 
carriers for gemcitabine transport in a drug delivery 
system? J. Mol Graphics Modell 2011; 29: 591–596. 
9. Denlinger CE, Rundall BK, Keller MD, Jones DR. 
Proteasome Inhibition Sensitizes Non–Small-Cell 
Lung Cancer to Gemcitabine-Induced Apoptosis, Ann 
Thorac Surg 2011; 78: 1207-1214. 
10. Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. A 
rapid and systematic review of the clinical 
effectiveness and costeffectiveness of paclitaxel, 
docetaxel, gemcitabine and vinorelbine in non-small-
cell lung cancer, Health Technol Assess 2001; 5(32): 
1-110. 
11. Tsai YH, Hsieh YH, Huang YB, Chang JS, Huang CT, 
Wu PC. Microemulsions for Intravesical Delivery of 
Gemcitabine, Chem Pharm Bull 2010; 58(11): 1461—
1465. 
12. Alkhatib M, Albishi H, Mahassni S. Impact of 
Nanoparticles on Cancer Therapy. Trop J  Pharm 
Res 2012; 11(6): 1001-1011. 
13. Bulmus V, Woodward  M,  Lin L, Murthy  N, Stayton P, 
Hoffman, A. A New pH-responsive and Glutathione-
reactive, Endosomal Membrane-disruptive Polymeric 
Carrier for Cntracellular Delivery of Biomolecular 
Drugs, J Control Release 2003; 93: 105-120. 
14. Alkhatib M., Albishi H. In vitro evaluation of antitumor 
activity of doxorubicin-loaded nanoemulsion in MCF-
7 human breast cancer cells. J Nanopart Res 2013; 
15: 1489-1503. 
15. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, 
Vistica D, Warren J., Bokesch H, Kenney S, Boyd 
MR. New colorimetric cytotoxicity assay for 
anticancer-drug screening. J Natl Cancer Inst 1990; 
82: 1107–1112. 
16. Von Der Maase H, Hansen SW, Roberts JT, Dogliotti L, 
Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, 
Lippert CM, et al. Gemcitabine and cisplatin versus 
methotrexate, vinblastine, doxorubicin, and cisplatin 
in advanced or metastatic bladder cancer: results of a 
large, randomized, multinational, multicenter, phase 
III study. J Clin Oncol 2000; 18 (17): 3068. 
17. Singh R, Mehra NK, Jain V, Jain NK. Gemcitabine-loaded 
smart carbon nanotubes for effective targeting to 
cancer cells. J. Drug Target 2013; 21(6): 581-92.  
Alkhatib et al 
Trop J Pharm Res, February 2014; 13(2): 224  
 
18. Wilk K, Zielinska K, Jarzycka A, Pietkiewicz. Human 
Erythrocyte Hemolysis Induced by Bioinspired Sugar 
Surfactants. Prog Coll Pol Sci 2011; 138: 189-192.   
19. Li Y, Le Maux S, Xiao H, McClements DJ. Emulsion 
based delivery systems for tributyrin, a potential 
colon cancer preventative agent. J Agric Food Chem 
2009; 57 (19): 9243–9249. 
20. Yang D, Yang F, Hu J, Long J,  Wang C, Fu D, Ni Q. 
Hydrophilic multi-walled carbon nanotubes decorated 
with magnetite nanoparticles as lymphatic targeted 
drug delivery vehicles, Chem Commun 2009; 29: 
4447-4449. 
 
